

EXPRESS MAIL NO.: EV 313 841 515 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	SMITH et al.	Confirmatio	n No.: 8561
Serial No.:	09/823,649	Art Unit:	1634
Filed:	March 30, 2001	PTO:	GOLDBERG, J.

For: HIGH TEMPERATURE

REVERSE TRANSCRIPTION USING MUTANT DNA

POLYMERASES

Attorney Docket No: 1803-343-999

THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

is dee	med mat	erial to the examination of the application.				
1.	Enclos	Enclosures accompanying this Third Information Disclosure Statement are:				
	1a.	A list of all patents, publications, applications, or other information submitted for consideration by the office.				
	1b.	A legible copy of:				
		☐ Each U.S. patent application publication and U.S. and foreign patent;				
		Each publication or that portion which caused it to be listed on the PTO-1449;				
		For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;				
		all other information or portion which caused it to be listed on the PTO-1449.				
	1c.	An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.				
	1d.	Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.				
2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b): Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d):				

		§1.491 in an international application;				
		☐ Before the mailing of the first Office action on the merits;				
		☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.				
3.		This Third Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.				
	3a.	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.				
	3b.	☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is: ☐ enclosed ☐ to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150 (1803-343-999).				
		(Item 3b to be checked if any reference known for more than 3 months)				
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.				
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: — enclosed. — to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.				
	The Ce	rtification Statement in Item 5 below is applicable.				
5.	\boxtimes	Certification Statement (applicable if Item 3a or Item 4 is checked)				
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.				
	5b.	In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
6.		This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).				
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.				
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No. , filed on , of which this application claims priority under 35				

		U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).					
	6c.	Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.					
7.		This is a Supplemental Information Disclosure Statement. (Check Item 7a)					
	7a.	This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .					
8.		In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:					
	8a.	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.					
	8b.	set forth in the application.					
	8c.	enclosed as an attachment hereto.					
9.		No fee is believed due, however, the Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150 (order no. 1803-343-999).					
10.		No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).					
		Respectfully submitted,					
Date:	<u>Augu</u>	st 19, 2003 42,983					
		Rahul Pathak (Reg. No.) For: Nikolaos C. George (39,201) PENNIE & EDMONDS LLP 3300 Hillview Avenue Palo Alto, CA 94304 (650) 493-4935					

				<u> </u>						
				ATTY DOCKET NO.		APPLICATION NO				
					1803-343-999		09/823,649			
SECOND	LIST	OF REFERENCES	CITED BY	APPLICANT	APPLICANT					
		(Up several sheets if i	necessary)		SMITH et al.					
		507			FILING DATE		GROUP			
	\bot	AUG 1 9 2003 2			March 30, 2001		1634			
	P.	To manufacture	U.S. PA	ATENT DOCUM	MENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	,	NAME	CLASS	SUBCLASS	FILING I		
			22			0050	00000000		Idill	
	<u> </u>									
							:			
	J			I			<u> </u>			
			FOREIGN	PATENT DOC	CUMENTS					
	DOCUMENT NUMBER DATE			co	UNTRY	SUBCLASS TRANSLATION				
		1110 05/1 4770	11/02/1004	Luuro			T	YES	NO	
	AJ	WO 95/14770	11/23/1994	WIPO					NO	
	<u> </u>		<u> </u>							
		OTHER REFERE	ENCES (Incl	uding Author, Ti	tle, Date, Pertinent	Pages, I	Etc.)			
	AK	SELNER, Loryn and TUI	RBETT, Gavin,	"Comparison of Thr	ee RT-PCR Methods,"	BioTechn	iques (1998)	25:230-23	4	
		(Royal Perth Hospital).								
										
				,						
EXAMINER				DATE	CONSIDERED					
*EXAMINER:	Initial if	reference considered, whether	or not citation is	in conformance with N	1PEP 609; Draw line thro	ugh citation	if not in confo	rmance and	not	
considered. Inc	lude cop	y of this form with next comm	unication to applic	cant.						